Testing effectiveness (Phase 2)Active Not RecruitingNCT05554328
What this trial is testing
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Who this might be right for
Recurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+1 more
National Cancer Institute (NCI) 165